Abstract
PCSK9 proprotein convertase subtilisin/kexin type (PCSK9) protein plays an important role in LDL cholesterol (LDL-C) metabolism, due to its role in the degradation of the LDL receptor. Preliminary clinical data of PCSK9 inhibition are quite promising and indicate that PCSK9 inhibition may be a novel strategy for the treatment of dyslipidemia particularly for those with refractory hypercholesterolemia, statin intolerance, or an elevated lipoprotein (a) level and associated cardiovascular diseases. Furthermore, development of PCSK9 inhibitor is an excellent example of “bench to bedside” concept where discovery of a genetic mutation was translated into a novel therapy to address unmet clinical needs. Although several approaches have been attempted to inhibit PCSK9 activity including small molecules, gene silencing and inhibitory antibodies, the most promising approach appears to be the use of monoclonal antibodies with a 50 -70% LDL cholesterol reduction on top of maximal doses of statins. In this article, we review the pharmacology of PCSK9 and summarize findings from key clinical studies using PCSK9 inhibitors.
Keywords: Antibodies, atherosclerosis, cardiovascular disease, cholesterol, dyslipidemia, inhibitors, lipoprotein metabolism, lipoprotein receptors, low density, proprotein convertase subtilisin/kexin type 9.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and LDL Lowering in the Contemporary Management of Dyslipidemia
Volume: 11 Issue: 4
Author(s): Maryna Popp Switzer, Azikiwe C. Nwosu, Zinnia San Juan and Debabrata Mukherjee
Affiliation:
Keywords: Antibodies, atherosclerosis, cardiovascular disease, cholesterol, dyslipidemia, inhibitors, lipoprotein metabolism, lipoprotein receptors, low density, proprotein convertase subtilisin/kexin type 9.
Abstract: PCSK9 proprotein convertase subtilisin/kexin type (PCSK9) protein plays an important role in LDL cholesterol (LDL-C) metabolism, due to its role in the degradation of the LDL receptor. Preliminary clinical data of PCSK9 inhibition are quite promising and indicate that PCSK9 inhibition may be a novel strategy for the treatment of dyslipidemia particularly for those with refractory hypercholesterolemia, statin intolerance, or an elevated lipoprotein (a) level and associated cardiovascular diseases. Furthermore, development of PCSK9 inhibitor is an excellent example of “bench to bedside” concept where discovery of a genetic mutation was translated into a novel therapy to address unmet clinical needs. Although several approaches have been attempted to inhibit PCSK9 activity including small molecules, gene silencing and inhibitory antibodies, the most promising approach appears to be the use of monoclonal antibodies with a 50 -70% LDL cholesterol reduction on top of maximal doses of statins. In this article, we review the pharmacology of PCSK9 and summarize findings from key clinical studies using PCSK9 inhibitors.
Export Options
About this article
Cite this article as:
Switzer Popp Maryna, Nwosu C. Azikiwe, Juan San Zinnia and Mukherjee Debabrata, Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and LDL Lowering in the Contemporary Management of Dyslipidemia, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (4) . https://dx.doi.org/10.2174/1871525712999140303123027
DOI https://dx.doi.org/10.2174/1871525712999140303123027 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alzheimer Disease and Type 2 Diabetes Mellitus: The Link to Tyrosine Hydroxylase and Probable Nutritional Strategies
CNS & Neurological Disorders - Drug Targets The NPC1L1 Inhibitor Ezetimibe in the Treatment of the Dyslipidemia in Patients Affected by the Metabolic Syndrome: Evidences and Perspectives
Current Enzyme Inhibition Activation of Macrophages: Establishing a Role for Polysaccharides in Drug Delivery Strategies Envisaging Antibacterial Therapy
Current Pharmaceutical Design The Interaction of Dietary Fibres with the Colon
Current Nutrition & Food Science tPA in the Central Nervous System: Relations Between tPA and Cell Surface LRPs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Cysteine Proteinases of Trypanosome Parasites Novel Targets for Chemotherapy
Current Drug Targets Effect of Flavonoids on Human Health: Old Subjects but New Challenges
Recent Patents on Biotechnology Stabilization of Neutral NH2-R-COOH Form of the Antihypertensive Peptides L-Valyl-L-Prolyl-L-Proline and L-Isoleucyl-L-Prolyl-L-Proline
Protein & Peptide Letters Control of Menopausal Transition through Physical Exercises
Current Women`s Health Reviews Contrast Media in Cardiovascular Magnetic Resonance
Current Pharmaceutical Design Complementary and Alternative Medicine for the Treatment of Insomnia: An Overview of Scientific Evidence from 2008 to 2018
Current Vascular Pharmacology Use of Metformin and Survival of Diabetic Women with Breast Cancer
Current Drug Safety Current Trends in the Chemotherapy of Colorectal Cancer
Current Medicinal Chemistry Drug Withdrawal and Hyperphagia: Lessons from Tobacco and Other Drugs
Current Pharmaceutical Design Imidazoline Receptor Agonists for Managing Hypertension May Hold Promise for Treatment of Intracerebral Hemorrhage
Current Molecular Medicine Severe Hyponatremia and Other Electrolyte Disturbances Associated with Indapamide
Current Drug Safety Fish Oil Supplementation: A Matter of DHA Enzymatic/Non-Enzymatic Oxidation Balance?
Current Nutrition & Food Science The Framingham Brain Donation Program: Neuropathology Along the Cognitive Continuum
Current Alzheimer Research Gum-Chewing and Headache: An Underestimated Trigger of Headache Pain in Migraineurs?
CNS & Neurological Disorders - Drug Targets Protein Oxidative Modification in the Aging Organism and the Role of the Ubiquitin Proteasomal System
Current Pharmaceutical Design